Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 7.8% on Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares fell 7.8% on Friday following insider selling activity. The company traded as low as $3.48 and last traded at $3.4650. Approximately 7,669,253 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 18,195,320 shares. The stock had previously closed at $3.76.

Specifically, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

Several brokerages recently commented on RXRX. JPMorgan Chase & Co. cut their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen cut Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, Morgan Stanley raised their price target on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $1.84 billion, a P/E ratio of -2.89 and a beta of 1.00. The firm has a 50 day moving average of $3.34 and a 200-day moving average of $3.64. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same period in the previous year, the company posted ($0.50) EPS. Recursion Pharmaceuticals’s revenue was down 56.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $31,000. Integral Investment Advisors Inc. purchased a new position in Recursion Pharmaceuticals during the 1st quarter valued at about $39,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $41,000. MQS Management LLC bought a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, Allworth Financial LP lifted its position in shares of Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.